RaaS Report On Harvest Technology Group (ASX:HTG)
Please see below a link to a report released by RaaS Advisory on Harvest Technology Group. We note that this… Read more
Nyrada Corporate Presentation Jun 2022
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation that will be… Read more
Nyrada Unveils Target of its Brain Injury Program as TRPC Ion Channels & Provides Phase I Study Update
• Brain Injury Program target revealed as versatile TRPC ion channels • NYR-BI02 is a potent blocker of three TRPC… Read more
Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
Highlights: • IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed •… Read more
Incannex Healthcare Limited (ASX:IHL) – Incannex Announces Positive Results From Phase 2 Clinical Trial
Incannex (NASDAQ: IXHL) (ASX: IHL) announced positive results from the phase 2 clinical trial investigating the effect of IHL-42X for… Read more
Incannex – Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea
Melbourne, Australia, May 17, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical… Read more
Nyrada – European Patent to be Granted for Cholesterol-Lowering Drug
The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9…. Read more
Incannex – APIRx Pharmaceuticals Acquisition May 2022
The acquisition of APIRx delivers a strong portfolio of patented drug candidates, with 22 development programs covering a total addressable… Read more
Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC
Melbourne, Australia, May 12, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical… Read more
